Evidence map›Paper›PMID 38550554›Full record

ArticleExpert review of precision medicine and drug development2024

Advances in the field of developing biomarkers for re-irradiation: a how-to guide to small, powerful data sets and artificial intelligence.

Chaudhry Huma, Lee Hawon, Jagasia Sarisha, Tasci Erdal, Camphausen Kevin, Krauze Andra Valentina

Abstract read
In one paragraph

Article in Expert review of precision medicine and drug development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chaudhry HumaRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.
Lee HawonRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.
Jagasia SarishaRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.
Tasci ErdalRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.
Camphausen KevinRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.
Krauze Andra ValentinaRadiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Bethesda, MD, 20892, United States.

Funding

Radiation Oncology Branch - Radiation ClinicZIDBC010990 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2009 to 2025
$136.0M
Radiation Oncology Branch - Radiation ClinicZ01BC010990 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CAMPHAUSEN, KEVIN · 2008 to 2008
$4.8M
Prognostic and predictive clinical and proteomic biomarker discovery in GBMZIABC012094 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAUZE, ANDRA · 2022 to 2025
$847k
Intramural NIH HHS Z01 BC010990Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC012094Intramural NIH HHS ZID BC010990
6 · The paper itself

Abstract

Introduction: Patient selection remains challenging as the clinical use of re-irradiation (re-RT) increases. Re-RT data is limited to retrospective studies and small prospective single-institution reports, resulting in small, heterogenous data sets. Validated prognostic and predictive biomarkers are derived from large-volume studies with long-term follow-up. This review aims to examine existing re-RT publications and available data sets and discuss strategies using artificial intelligence (AI) to approach small data sets to optimize the use of re-RT data. Methods: Re-RT publications were identified where associated public data was present. The existing literature on small data sets to identify biomarkers was also explored. Results: Publications with associated public data were identified, with glioma and nasopharyngeal cancers emerging as the most common tumor sites where the use of re-RT was the primary management approach. Existing and emerging AI strategies have been used to approach small data sets including data generation, augmentation, discovery, and transfer learning. Conclusions: Further data is needed to generate adaptive frameworks, improve the collection of specimens for molecular analysis, and improve the interpretability of results in re-RT data.

Indexed as

AIbiomarkersclinical datacomputational analysisdata managementdatasetshumanmachine learningpublic datareirradiation

Identifiers

PMID38550554
PMCPMC10972602

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.